C-Peptide

产品名称：C-Peptide ELISA
产    地：Demeditec 
产品货号：DE1293
产品规格：96 Tests
产品说明：
Special remarks: This product has been 510(k) cleared by the FDA/USA.
Insulin is synthesized in the pancreatic beta cells as a 6000 MW component of an 86 amino acid polypeptide called proinsulin. Proinsulin is subsequently cleaved enzymatically, releasing insulin into the circulation along with a residual 3000 MW fragment called connection ("C") peptide, so-named because it connects A and B chains of insulin within the proinsulin molecule. Human C-Peptide, a 31 amino acid residue peptide, has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C?Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin.
The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin.
Thus, low C-Peptide levels are to be expected when insulin is diminished (as in insulin-dependent diabetes) or suppressed (as a normal response to exogenous insulin), whereas elevated C-Peptide levels may result from the increased β-cell activity observed in insulinomas.
C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests.
C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
Clinical Indications for the DEMEDITEC C-Peptide ELISA
Assessment of residual ß-cell function in diabetics under insulin therapy
Detection and monitoring of the remission phase of type I diabetes
Adjunct in the differential diagnosis between type I (insulin dependent) and type II (non-insulin-dependent) diabetes
Diagnosis of insulin-induced factitious hypoglycemia.
Contribution to the diagnosis of insulinoma (insulin suppression test)
Prognostic index of fetal outcome in pregnant diabetic women
Evaluation of insulin secretion in liver disease
Monitoring of pancreasectomy
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位，公司提供的产品涵盖了二十多个国家近五十万种产品，而且产品的数量与信息在不断的增长和更新，公司提供的产品能够使生命科学工作者加快对生物化学，分子生物学，细胞生物学以及蛋白质组学研究的认知，以及分子诊断和临床医学领域的应用。

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!